FX 125L

Drug Profile

FX 125L

Alternative Names: FX125L

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Funxional Therapeutics
  • Developer Funxional Therapeutics; STX Pharma
  • Class Small molecules
  • Mechanism of Action Chemokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (PO)
  • 01 Jan 2015 STX Pharma completed a phase-II clinical trial in Asthma in United Kingdom (PO) (EudraCT2014-002052-84)
  • 24 Jul 2014 Phase-II clinical trials in Asthma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top